Scientists from Harvard University & Mayo Clinic validate our ionic liquid platform

  • Home
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
  • Our Technology
    • Our Team
    • Career
    • Press Releases
    • In the news
    • Publications
  • Contact Us
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • Our Technology
  • Contact Us
image267

Deep eutectic ionic liquids for therapeutics

Deep eutectic ionic liquids for therapeuticsDeep eutectic ionic liquids for therapeuticsDeep eutectic ionic liquids for therapeutics

Transforming ionic liquids into healthcare solutions

Deep eutectic ionic liquids for therapeutics

Deep eutectic ionic liquids for therapeuticsDeep eutectic ionic liquids for therapeuticsDeep eutectic ionic liquids for therapeutics

Transforming ionic liquids into healthcare solutions

image268

Who We Are

Our Advantage

Our Mission

CAGE Bio Inc., currently a resident company at Johnson & Johnson Innovation, JLABS @ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.

image269

Our Mission

Our Advantage

Our Mission

We believe that systemic exposure to drugs should be an exception. Our mission is to develop highly

effective products for localized treatment thereby minimizing side effects from systemic exposure.

image270

Our Advantage

Our Advantage

Our Advantage

Deep eutectic ionic liquids exhibit broad-spectrum antimicrobial action in addition to exceptional solvation and permeation enhancement. Deep eutectic ionic liquids have shown the ability to deliver proteins (eg insulin) and charged macromolecules (eg siRNA) across the stratum corneum.

LEADERSHIP

image271

Nitin Joshi, CEO

Ravi Srinivasan, Chairman of Board

Samir Mitragotri, Co-Founder

20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company.

image272

Samir Mitragotri, Co-Founder

Ravi Srinivasan, Chairman of Board

Samir Mitragotri, Co-Founder

Professor, Bioengineering and Biologically Inspired Engineering, Harvard University.

Member of the U.S. National Academy of Engineering, National Institute of Medicine, National Academy of Inventors.

image273

Ravi Srinivasan, Chairman of Board

Ravi Srinivasan, Chairman of Board

Ravi Srinivasan, Chairman of Board

Serial biotech entrepreneur, multiple startups and exits. StrataGent(acquired by Corium), StemPar, OncoNano(raised $100M), Symyx, ForSightV5 (acquired by Allergan for $90M).


Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept
image274

Welcome! Check out our latest news.

Scientists from Harvard University and Mayo Clinic validate our ionic liquid platform for treating large hepatocellular tumors to help bridge more patients to liver transplantation. 

Learn more